Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback